ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2020PRNewsWire • 02/11/21
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2020PRNewsWire • 12/15/20
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 32nd EORTC-NCI-AACR SymposiumPRNewsWire • 10/24/20
ESSA Pharma to Participate in Oppenheimer Fall Healthcare Life Science & MedTech SummitPRNewsWire • 09/21/20
ESSA Pharma Announces the Presentation of Additional Preclinical Data for EPI-7386 at the ESMO Virtual Congress 2020PRNewsWire • 09/17/20
ESSA Pharma Announces Fast Track Designation Granted by the FDA to EPI-7386 for the Treatment of Metastatic Castration-Resistant Prostate CancerPRNewsWire • 09/14/20
ESSA's Novel Prostate Cancer Treatment In Clinical Trial: Pfizer Is New Lead InvestorSeeking Alpha • 08/19/20
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2020PRNewsWire • 08/07/20
ESSA Pharma Completes Public Offering for Aggregate Gross Proceeds of US$48,990,000PRNewsWire • 07/31/20
ESSA Pharma Announces First Patient Dosed in a Phase 1 Clinical Trial of EPI-7386 for Metastatic Castration-Resistant Prostrate CancerPRNewsWire • 07/15/20
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at the 2020 American Association for Cancer Research Virtual Annual Meeting IIPRNewsWire • 06/22/20